Clinical trial · Interventional
Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma
Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma
NCT02482454CI-TRIAL-00028890active not recruitingPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with cholangiocarcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cholangiocarcinoma | Cholangiocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cytokine-induced killer cells | Biological | — | UNRESOLVED |
| Radiofrequency ablation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- RFA alone
- description
- Patients undergo radiofrequency ablation alone.
- interventionNames
- Procedure: Radiofrequency ablation
- type
- EXPERIMENTAL
- label
- RFA+CIK
- description
- Autologous cytokine-induced killer cells were transfer via venous one week after RFA
- interventionNames
- Procedure: Radiofrequency ablation
- Biological: Cytokine-induced killer cells
Primary outcomes (1)
- measure
- Recurrence-free survival
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically confirmed cholangiocarcinoma * Primary lesions (cholangiocarcinoma) are not resected * Serum bilirubin level of 2.0 mg/dl or less. * Performance status of 0 or 1. * Expected survival of 1 year or more. * Informed consent from the patient. Exclusion Criteria: * With extrahepatic metastases * With other neoplastic disease that is measurable or being treated other than cholangiocarcinoma.
References
Publications (0)
Data not yet available
No reference posted for this study.